Netupitant
Grundinformationen
- CAS
290297-26-6- Standard-SMILES
Cc1ccccc1-c1cc(N2CCN(C)CC2)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1- InChIKey
WAXQNWCZJDTGBU-UHFFFAOYSA-N- Summenformel
- C30H32F6N4O
- Durchschnittliche Molmasse
- 578,6 g/mol
- Monoisotopische Masse
- 578,24803063
Überblick
Netupitant is a monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2-[3,5-bis(trifluoromethyl)phenyl]-2-methylpropanoic acid with the secondary amino group of N-methyl-4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-amine; an antiemetic used in combination with palonosetron hydrochloride (under the trade name Akynzeo) to treat nausea and vomiting in patients undergoing cancer chemotherapy. It has a role as an antiemetic and a neurokinin-1 receptor antagonist. It is a member of toluenes, a monocarboxylic acid amide, an organofluorine compound, an aminopyridine, a N-alkylpiperazine and a N-arylpiperazine.
Namen und Bezeichner
- Bevorzugter Name
- Netupitant
- IUPAC
- 2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)-3-pyridinyl]propanamide
- Englischer Name
- 2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl]propanamide
- Summenformel
- C30H32F6N4O
- Molmasse
- 578.59
Namen und Synonyme
Netupitant290297-26-62-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl]propanamideRo 67-3189/000Ro-67-3189Ro-6731890007732P08TIRCHEBI:85155DTXSID50183271RO-67-3189/000AKYNZEO CAPSULE COMPONENT NETUPITANTNETUPITANT COMPONENT AKYNZEO CAPSULE
Weitere Namen anzeigen
NETUPITANT (RO 67-31898)NetupitanCID-6451149CID 6451149Ro 67-31898NataipitideRo 67-31898/000Netupitant(CID-6451149)
D051522-(3,5-Bis(trifluoromethyl)phenyl)-N-methyl-N-(4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl)-2-methylpropanamidenetupitantum2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl)propanamideCID6451149RefChem:832394DTXCID60105762RO 673189000
Datenbank-Bezeichner
Eigenschaften
Berechnete Struktureigenschaften
- XLogP
- 6,8
- Polarare Oberfläche (TPSA)
- 39,7 Ų
- H-Brücken-Donoren
- 0
- H-Brücken-Akzeptoren
- 10
- Frei drehbare Bindungen
- 5
- Schwere Atome
- 41
- Formalladung
- 0
- Komplexität
- 865
Experimentelle und physikochemische Eigenschaften
Drugs
Pharmaceuticals -> Alimentary tract and metabolism -> Antiemetics and antinauseants
Pharmaceuticals -> Listed in ZINC15
Human Drugs
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Physikochemische Eigenschaften
- Schmelzpunkt
- 156.2 · 156.2-160.0 °C
- Siedepunkt
- 597.4 · 597.4±50.0 °C(Predicted)
- Dichte
- 1.255 · 1.255
- storage temp.
- 2 · 2-8°C
- Löslichkeit
- Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
- pka
- 7.89 · 7.89±0.38(Predicted)
- Aggregatzustand
- Solid
- Farbe
- White to Off-White
- InChIKey
- WAXQNWCZJDTGBU-UHFFFAOYSA-N
- SMILES
- C(N(C)C1=C(C2C=CC=CC=2C)C=C(N2CCN(C)CC2)N=C1)(=O)C(C1C=C(C(F)(F)F)C=C(C(F)(F)F)C=1)(C)C
Sicherheit und Regulatorisches
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
GHS-Klassifizierung
GHS Classification
Warning
H302 (50%): Harmful if swallowed [Warning Acute toxicity, oral]
P203, P264, P264+P265, P270, P280, P301+P317, P302+P352, P305+P351+P338, P318, P321, P330, P332+P317, P337+P317, P362+P364, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 2 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Gefahrenhinweise
Hazard Classes and CategoriesAcute Tox. 4 (50%)
Sicherheitsdaten
- wgk
- WGK 3
- Speicherklasse
- 11 - Combustible Solids
- Hazard Classifications
- Eye Irrit. 2Skin Irrit. 2
Chemie und Industrie
Pharmakologische Informationen
Protein Binding> 99.5% at drug concentrations ranging from 10-1300 ng/mL.
Mechanism of Action
Delayed emesis (vomiting) has been largely associated with the activation of tachykinin family neurokinin 1 (NK1) receptors (broadly distributed in the central and peripheral nervous systems) by substance P. As shown in in vitro and in vivo studies, netupitant inhibits substance P mediated responses.
Biological Half-Life96 hours with CV% of 61.
Metabolism/Metabolites
Once absorbed, netupitant is extensively metabolized to form three major metabolites: desmethyl derivative, M1; N-oxide derivative, M2; and OH-methyl derivative, M3. Metabolism is mediated primarily by CYP3A4 and to a lesser extent by CYP2C9 and CYP2D6. Metabolites M1, M2 and M3 were shown to bind to the substance P/neurokinin 1 (NK1) receptor.
FDA Pharmacological Classification
7732P08TIR
NETUPITANT
Mechanisms of Action [MoA] - Neurokinin 1 Antagonists
Established Pharmacologic Class [EPC] - Substance P/Neurokinin-1 Receptor Antagonist
Mechanisms of Action [MoA] - Cytochrome P450 3A4 Inhibitors
Mechanisms of Action [MoA] - P-Glycoprotein Inhibitors
Absorption, Distribution and Excretion
Upon oral administration of a single dose of netupitant, netupitant started to be measurable in plasma between 15 minutes and 3 hours after dosing. Plasma concentrations reached Cmax in approximately 5 hours. There was a greater than dose-proportional increase in the systemic exposure with the dose increase from 10 mg to 300 mg and a dose-proportional increase in systemic exposure with a dose increase from 300 mg to 450 mg.
Primarily fecal.
In cancer patients, Vz/F: 1982 ± 906 L (mean ± SD).
Estimated systemic clearance of 20.3 ± 9.2 L/h (mean ± SD).
Anwendungen
Zugehörige Reaktionen
8
Notizen zur Verbindung
Wird geladen…